Serimmune Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 24

Employees

  • Latest Deal Type
  • M&A

Serimmune General Information

Description

Developer of an immune intelligence platform designed to decode the human immune response and empower the growth of diagnostics, vaccines, and therapeutics. The company's machine learning-based platform applies bacterial display peptide libraries, sequencing, and custom bioinformatics to map the distinct antibodies within a repertoire to antigens associated with infections, allergens, microbiome organisms, autoimmune diseases, and cancers, enabling medical practitioners to combat infectious and autoimmune diseases.

Contact Information

Website
www.serimmune.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 150 Castilian Drive
  • Suite 100
  • Goleta, CA 93117
  • United States
+1 (805)
Primary Industry
Biotechnology
Acquirer
Infinity Bio
Vertical(s)
Artificial Intelligence & Machine Learning, HealthTech, Life Sciences
Corporate Office
  • 150 Castilian Drive
  • Suite 100
  • Goleta, CA 93117
  • United States
+1 (805)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Serimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 18-Jun-2025 Completed Generating Revenue
9. Later Stage VC 13-Nov-2023 Completed Generating Revenue
8. Grant 31-Dec-2020 Completed Generating Revenue
7. Later Stage VC (Series C) 11-Sep-2020 Completed Generating Revenue
6. Grant 01-Jan-2019 Completed Generating Revenue
5. Early Stage VC 20-Jun-2017 Completed Generating Revenue
4. Grant 01-Jan-2017 Completed Generating Revenue
3. Early Stage VC (Series B) 30-Dec-2016 Completed Generating Revenue
2. Grant 01-Jan-2016 $225K $850K Completed Generating Revenue
1. Early Stage VC (Series A) 13-Jan-2015 $850K $850K Completed Generating Revenue
To view Serimmune’s complete valuation and funding history, request access »

Serimmune Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C
Series B
Series A 988,369 $0.000100 $0.86 $0.86 1x $0.86 8.86%
To view Serimmune’s complete cap table history, request access »

Serimmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an immune intelligence platform designed to decode the human immune response and empower the growth of diag
Biotechnology
Goleta, CA
24 As of 2023

Farmington, CT
 

Rockville, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Serimmune Competitors (58)

One of Serimmune’s 58 competitors is CaroGen, a Venture Capital-Backed company based in Farmington, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CaroGen Venture Capital-Backed Farmington, CT
Regenxbio Formerly VC-backed Rockville, MD
Novus Biologicals Formerly PE-Backed Centennial, CO
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
NOVADIP Venture Capital-Backed Mont-Saint-Guibert, Belgium
You’re viewing 5 of 58 competitors. Get the full list »

Serimmune Patents

  • 40

    Total Documents Applications and Grants

  • Total Patents Families

  • 20

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

Serimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240241131-A1 Global protein-based immunome wide association studies Pending 07-Oct-2021
WO-2023060267-A1 Global protein-based immunome wide association studies Inactive 07-Oct-2021
US-20240192208-A1 Serum antibody profiling for leptospirosis Pending 13-May-2021
WO-2022241256-A1 Serum antibody profiling for leptospirosis Inactive 13-May-2021
CA-3184250-A1 Sars-cov-2 serum antibody profiling Pending 24-Jun-2020 C07K17/00
To view Serimmune’s complete patent history, request access »

Serimmune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Serimmune Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Illumina Ventures Venture Capital Minority
Labcorp Venture Fund Corporate Venture Capital Minority
Merck Corporation Minority
National Institute Of Allergy and Infectious Diseases Government
U.S. Department of Health and Human Services Government
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Serimmune FAQs

  • When was Serimmune founded?

    Serimmune was founded in 2014.

  • Where is Serimmune headquartered?

    Serimmune is headquartered in Goleta, CA.

  • What is the size of Serimmune?

    Serimmune has 24 total employees.

  • What industry is Serimmune in?

    Serimmune’s primary industry is Biotechnology.

  • Is Serimmune a private or public company?

    Serimmune is a Private company.

  • What is Serimmune’s current revenue?

    The current revenue for Serimmune is .

  • How much funding has Serimmune raised over time?

    Serimmune has raised $34.9M.

  • Who are Serimmune’s investors?

    Illumina Ventures, Labcorp Venture Fund, Merck, National Institute Of Allergy and Infectious Diseases, and U.S. Department of Health and Human Services are 5 of 6 investors who have invested in Serimmune.

  • Who are Serimmune’s competitors?

    CaroGen, Regenxbio, Novus Biologicals, Genetix Biotherapeutics, and NOVADIP are some of the 58 competitors of Serimmune.

  • When was Serimmune acquired?

    Serimmune was acquired on 18-Jun-2025.

  • Who acquired Serimmune?

    Serimmune was acquired by Infinity Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process